Abbott Laboratories (ABT)vsGlaukos Corp (GKOS)
ABT
Abbott Laboratories
$109.96
-3.23%
HEALTHCARE · Cap: $184.98B
GKOS
Glaukos Corp
$224.41
+2.01%
HEALTHCARE · Cap: $10.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 7770% more annual revenue ($48.23B vs $612.84M). ABT leads profitability with a 9.8% profit margin vs -30.7%. ABT appears more attractively valued with a PEG of 1.52. ABT earns a higher WallStSmart Score of 52/100 (C-).
ABT
Buy52
out of 100
Grade: C-
GKOS
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.6%
Fair Value
$76.57
Current Price
$109.96
$33.39 premium
Margin of Safety
+8.6%
Fair Value
$119.31
Current Price
$224.41
$105.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Generating 1.2B in free cash flow
Revenue surging 49.5% year-over-year
Earnings expanding 1896.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 43.7%
Expensive relative to growth rate
Trading at 19.3x book value
Weak financial health signals
ROE of -28.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 14.5% demonstrates continued momentum.
Bull Case : GKOS
The strongest argument for GKOS centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 49.5% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : GKOS
The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.
Key Dynamics to Monitor
ABT profiles as a value stock while GKOS is a hypergrowth play — different risk/reward profiles.
GKOS carries more volatility with a beta of 0.69 — expect wider price swings.
GKOS is growing revenue faster at 49.5% — sustainability is the question.
ABT generates stronger free cash flow (1.2B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (52/100 vs 45/100) and 14.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Glaukos Corp
HEALTHCARE · MEDICAL DEVICES · USA
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?